Navigation Links
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
Date:1/8/2014

hi Sankyo's impressive capabilities, global reach, and open, collaborative culture make them ideal partners," said Jake Reder, Ph.D., President and Chief Executive Officer of Celdara Medical. "The team at Celdara Medical is excited to work hand-in-hand with Daiichi Sankyo on some of the most challenging problems in human health."

About Daiichi Sankyo


The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information about Daiichi Sankyo, please visit www.daiichisankyo.com.   

About Virtici, LLC

Founded in 2011, Virtici is a privately held product-development company headquartered in Seattle, Washington. Virtici's mission is to improve quality of life and save lives, and is primarily developing products to improve the way we diagnose and treat cancer, autoimmunity, and cardiovascular/metabolic diseases. Virtici, working closely with our affiliate Celdara Medical, partners with inventors and their research institutions, bringing the business and finance expertise to accelerate product development. Working with its partners in the pharmaceutical industry, Virtici connects the entire product development lifecycle by improving innovation, enhancing discovery and increasing product development efficiencies. Fo
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
6. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
10. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
11. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... RIDGEWOOD, N.J. , Feb. 27, 2015 ... antibiotics has helped cut the rate of infection with ... nearly 40 percent. Clostridium difficile, or C.diff, ... diarrhea to life-threatening inflammation of the colon. A recent ... "Burden of Clostridium difficile Infection in the ...
(Date:2/27/2015)... KING OF PRUSSIA, Pa. , Feb. 27, 2015 ... part of its ongoing commitment to the global bleeding ... it is donating 2 million international units (IUs) of ... WFH is an international not-for- profit organization which has ... and other inherited bleeding disorders. The donation supports the ...
(Date:2/27/2015)... , February 27, 2015 ... sein bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) ... -     ... die ein neuartiges Herzüberwachungssystem für Patienten mit ... bekannt, dass sie ein Finanzierungsvorhaben über 5 ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... CVS Caremark Corporation (NYSE: CVS ) today ... will be making a presentation to investors at the ... 2011. Mr. Merlo is scheduled to present at 2:00 ... audio webcast of the presentation will be broadcast simultaneously ...
... May 20, 2011 BD Biosciences, a segment of BD ... today the BD FACSVerse™ Flow Cytometer, a flexible, reliable and ... support a wide range of research applications.   ... from the ground up, with three foundations in mind,” said ...
Cached Medicine Technology:BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 2BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 3
(Date:2/28/2015)... In a recent episode of SCI ... Change Athlete Development Services and Consultancy talks with ... athlete development and player engagement during and after their ... athletes face and how off-field activities are a critical ... involved in athlete development issues while in graduate school ...
(Date:2/28/2015)... Oregon (PRWEB) February 28, 2015 The ... Oregon, is offering a new special. Throughout all ... relines. , This service can ... sleep problems and pain. Patients may notice certain symptoms ... need relining. These symptoms include: , 1.    Pain, clicking, ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Indosoft ... software suite for Asterisk, are pleased to announce the ... successful 5.7 and 5.8 versions of Q-Suite, this new ... as a number of new features to the leading ... 2015. , Q-Suite 5.9 will add features to enhance ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... New York, NY (PRWEB) February 28, 2015 ... to discuss federal testosterone lawsuits that have been filed ... scheduled for the second week in March, the Firm ... the Court’s website, parties involved in the federal litigation ... to address matters related to prescription therapy treatments designed ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4
... the disease, , , WEDNESDAY, April 15 (HealthDay News) ... the tracking of changes in cancer cells, according ... Medicine. , The technology uses specially designed dye-containing ... or on a single cell. , Current single-flow ...
... RequirementsTAMPA, Fla., April 15 Sage Software Healthcare, ... today announced that The Certification Commission for Healthcare ... Intergy EHR, as a CCHIT Certified(R) ... certified for Child Health and Cardiovascular Medicine, and ...
... Emory University, developed a test in nonhuman primates that ... cognitive impairment (MCI) in humans. The researchers hope the ... of Alzheimer,s disease. The test, which is featured in ... of Alzheimer,s Disease and Other Dementias , is helping ...
... Dinotefuran and Pyriproxyfen Combination Delivers Safe and Effective Control ... April 15 Summit VetPharm announces the introduction of ... flea control product containing dinotefuran and pyriproxyfen in combination ... that protects your dog from all stages of fleas ...
... Voice-Assisted Care and Pathway Health Services Bring Better ... Facilities in Long-Term CarePITTSBURGH, April 15 Vocollect ... a nationally recognized consulting and management company for ... home care markets, announce an agreement whereby Pathway ...
... April 15 ... landmark in the employee phase of the "Our House is ... and Kemmons Wilson Family Center for Good Grief as they ... began in November of 2008, with 60 employee volunteers across ...
Cached Medicine News:Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Yerkes researchers use eye tracking to detect mild dementia in humans 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 2Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 3Health News:Summit VetPharm Offers New Flea Topical Vectra for Dogs & Puppies(TM) For Long-Lasting Protection 4Health News:Pathway Health Services and Vocollect Healthcare Systems Announce Strategic Partnership 2Health News:Baptist Colleagues Raise $1 Million for Baptist Trinity Hospice House and Kemmons Wilson Family Center for Good Grief 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: